| Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC (NCT05158491) | JenKem Technology Co., Ltd. | 2021-11-11 |
| Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC (NCT05027100) | Haibo Zhang | 2021-09-30 |
| Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) (NCT04727853) | CSPC Ouyi Pharmaceutical Co., Ltd. | 2021-03-01 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. (NCT04285866) | Fundación GECP | 2020-05-21 |
| Prospective Clinicogenomic Program (NCT04180176) | Genentech, Inc. | 2019-12-13 |
| A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors (NCT03811652) | MedImmune LLC | 2018-12-20 |
| A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors (NCT03708328) | Hoffmann-La Roche | 2018-10-15 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228) | VM Oncology, LLC | 2018-06-08 |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (NCT03460977) | Pfizer | 2018-04-17 |
| Pembrolizumab in Untreated Extensive SCLC (NCT02580994) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-12-08 |
| Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer (NCT03505515) | Bristol-Myers Squibb | 2017-12-07 |
| Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas (NCT02030184) | University of Maryland, Baltimore | 2017-06-01 |
| A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) (NCT03066778) | Merck Sharp & Dohme LLC | 2017-05-02 |
| Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC) (NCT02934503) | NYU Langone Health | 2017-01-23 |
| Study in Patients With SCLC of Veliparib in Combination With Topotecan (NCT03227016) | Central European Society for Anticancer Drug Research | 2016-10-01 |
| Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer (NCT02769832) | Muhammad Furqan | 2016-08-29 |
| Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer (NCT02748889) | Giuseppe Giaccone | 2016-03-01 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (NCT02628067) | Merck Sharp & Dohme LLC | 2015-12-18 |
| Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor (NCT02069158) | Cristiana Sessa | 2014-04-01 |
| A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy (NCT01904253) | Taiho Oncology, Inc. | 2013-07-01 |
| Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC) (NCT01210131) | Maastricht Radiation Oncology | 2013-07-01 |
| Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors (NCT01719861) | Joel Neal | 2012-10-01 |